City

Guangzhou (1)

Shanghai (1)

Condition

Lung Adenocarcinoma Stage IV (2)

EGFR Gene Mutation (1)

Lung Adenocarcinoma Stage III (1)

Overall Status

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China (1)

Zhou Chengzhi (1)

Collaborator

Intervention

bevacizumab (1)

furmonertinib (1)

tislelizumab (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

lung adenocarcinoma stage iv

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

Recruiting

Lung Adenocarcinoma Stage III
+2 more

Shanghai, Shanghai, China

Shanghai Pulmonary Hospital

Aug 13, 2022

Lung Adenocarcinoma Stage IV Trial in Guangzhou (Tislelizumab)

Unknown status

Lung Adenocarcinoma Stage IV

Tislelizumab

Guangzhou, Guangdong, China

Zhou Chengzhi

Mar 16, 2020